Cisplatin and Photophobia - a phase IV clinical study of FDA data

Summary:

Photophobia is reported as a side effect among people who take Cisplatin (cisplatin), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Dexamethasone, and have Diffuse large b-cell lymphoma stage iv.

The phase IV clinical study analyzes which people have Photophobia when taking Cisplatin. It is created by eHealthMe based on reports of 92,672 people who have side effects when taking Cisplatin from the FDA, and is updated regularly.

What is Cisplatin?

Cisplatin has active ingredients of cisplatin. It is often used in chemotherapy. eHealthMe is studying from 92,837 Cisplatin users. Check the latest studies of Cisplatin.

What is Photophobia?

Photophobia (extreme sensitivity to light) is found to be associated with 1,286 drugs and 1,832 conditions by eHealthMe. Check the latest studies of Photophobia.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 03, 2026

92,672 people reported to have side effects when taking Cisplatin.
Among them, 38 people (0.04%) have Photophobia.

Among these 38 people:

How long have people been on Cisplatin when they have Photophobia? *

What is the gender of people who have Photophobia when taking Cisplatin? *

female: 41.18 %
male: 58.82 %

What is the age of people who have Photophobia when taking Cisplatin? *

What are other drugs people take besides Cisplatin? *

What are other side effects people have besides Photophobia? *

Nausea (feeling of having an urge to vomit): 25 people, 65.79%
Headache (pain in head): 22 people, 57.89%
Nausea And Vomiting: 18 people, 47.37%
Diplopia (double vision): 10 people, 26.32%
Dyspnea (difficult or laboured breathing): 7 people, 18.42%
Fever: 6 people, 15.79%
Migraine (headache): 6 people, 15.79%
High Blood Pressure: 6 people, 15.79%
Vision Blurred: 6 people, 15.79%
Diarrhea: 5 people, 13.16%

What are the existing conditions these people have? *

Diffuse Large B-Cell Lymphoma Stage Iv (cancer of b cells, a type of white blood cell-stage iv): 4 people, 10.53%
Rhinitis (a medical term for irritation and inflammation of the mucous membrane inside the nose): 3 people, 7.89%
Lung Cancer - Small Cell (lung cancer): 3 people, 7.89%
Bladder Cancer: 3 people, 7.89%
Squamous Cell Carcinoma (a cancer of a kind of epithelial cell): 2 people, 5.26%
Neoplasm Malignant (cancer tumour): 2 people, 5.26%
Lung Cancer - Non-Small Cell (lung cancer): 2 people, 5.26%
Jugular Vein Thrombosis (clot in jugular vein): 2 people, 5.26%
Testicular Germ Cell Cancer (germ cell cancer of testes): 1 person, 2.63%
Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 1 person, 2.63%

* Approximation only. Some reports may have incomplete information.

Do you take Cisplatin and have Photophobia?

- Check whether Photophobia is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Cisplatin:

Cisplatin (92,837 reports)

Photophobia treatments and more:

Photophobia (21,347 reports)

Browse all side effects of Cisplatin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Photophobia:

Photophobia (1,286 drugs)

Browse all the conditions that are associated with Photophobia:

Photophobia (1,832 conditions)

Related publications that referenced our studies

Schlumbrecht MP, Hehr K, "Cisplatin-induced bradycardia and the importance of the QT interval", Journal of Oncology Pharmacy Practice, 2015 Jan .
Schlumbrecht MP, Hehr K, "Cisplatin-induced bradycardia and the importance of the QT interval", Journal of Oncology Pharmacy Practice, 2015 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on cisplatin (the active ingredients of Cisplatin) and Cisplatin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.